8.30Open8.30Pre Close0 Volume0 Open Interest12.00Strike Price0.00Turnover1696.72%IV12.53%PremiumApr 11, 2025Expiry Date7.77Intrinsic Value100Multiplier1DDays to Expiry0.53Extrinsic Value100Contract SizeAmericanOptions Type-0.6967Delta0.0811Gamma0.51Leverage Ratio-0.5076Theta-0.0004Rho-0.35Eff Leverage0.0009Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet